Sign up
Pharma Capital

VolitionRx closes offering, raises US$8.4mln

The cancer blood test firm issued 3.5mln shares at US$2.40 a share in the offering
The group is focused on developing simple blood tests designed to help diagnose a range of cancers

Cancer testing firm VolitionRx Ltd (NYSE:VNRX) has raised US$8.4mln gross via its previously announced public offering, now closed.

It issued 3.5mln shares at US$2.40  a share.

"Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes," it said in the brief stock market statement Tuesday.

Oppenheimer & Co Inc. acted as the sole book-running manager.

Shares closed on Tuesday at US$2.34 each.

View full VNRX profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.